In the SURPASS program, gastrointestinal side effects associated with the use of tirzepatide were similar to those observed with semaglutide and GLP1-RA drugs in general, both in terms of frequency and duration [3]
In the STEP-1 obesity trial, semaglutide 2.4 mg weekly produced roughly 14.9% mean body-weight loss over 68 weeks ( Wilding et al., NEJM 2021 )
3206-A CLINICAL CHARACTERISTICS OF END-STAGE LIVER DISEASE COMPLICATED BY BACTERIAL OR FUNGAL INFECTIONS: A MULTI-CENTER RETROSPECTIVE STUDY FROM CENTRAL CHINA Wei Liu 1,2 , Qiuyu Cheng 1,2 , Yunhui Liu 1,2 , Zhongyuan Yang 1,2 , Meng Zhang 1,2 , Tingting Liu 1,2 , Yuxin Niu 1,2 , Xiaojing Wang 1,2 , Tao Chen 1,2 and Qin Ning 1,2 , (1)Institute and Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, (2)Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology Background: To analyze the clinical characteristics in patients with end-stage liver disease (ESLD) complicated by bacterial or fungal infections
Month 2: The Peak and the Pivot Weeks 5 through 8 represent the hardest stretch
Joint inflammation support: Patients with chronic joint pain, post-surgical joint swelling, or inflammatory conditions that keep flaring despite management